The current financial score of Treace Medical Concepts Inc is 6.05. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 45.38M, representing a year-over-year decrease of 4.24%, while its net profit experienced a year-over-year decrease of 8.77%.
The current valuation score of Treace Medical Concepts Inc is 7.96. Its current P/E ratio is -4.69, which is -72.59% below the recent high of -1.29 and -650.75% above the recent low of -35.24.
The current earnings forecast score of Treace Medical Concepts Inc is 6.00. The average price target is 5.50, with a high of 7.00 and a low of 4.50.
The current price momentum score of Treace Medical Concepts Inc is 4.35. Currently, the stock price is trading between the resistance level at 4.92 and the support level at 4.16, making it suitable for range-bound swing trading.
The current institutional shareholding score of Treace Medical Concepts Inc is 5.00. The latest institutional shareholding proportion is 58.61%, representing a quarter-over-quarter decrease of 4.20%. The largest institutional shareholder is James Simons, holding a total of 48.30K shares, representing 0.00% of shares outstanding, with 83.54% decrease in holdings.
The current risk assessment score of Treace Medical Concepts Inc is 3.07. The company's beta value is 1.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.